Cargando…

Child–Adult Transition in Sarcoidosis: A Series of 52 Patients

(1) Background: Pediatric sarcoidosis is a rare and mostly severe disease. Very few pediatric series with a prolonged follow-up are reported. We aimed to evaluate the evolution of pediatric sarcoidosis in adulthood. (2) Material and methods: Patients over 18-years-old with a pediatric-onset sarcoido...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauveau, Simon, Jeny, Florence, Montagne, Marie-Emeline, Abou Taam, Rola, Houdouin, Véronique, Meinzer, Ulrich, Delacourt, Christophe, Epaud, Ralph, Cohen Aubart, Fleur, Chapelon-Abric, Catherine, Israël-Biet, Dominique, Juvin, Karine, Dossier, Antoine, Bodaghi, Bahram, Prévot, Grégoire, Naccache, Jean-Marc, Mattioni, Sarah, Deschildre, Antoine, Brouard, Jacques, Tazi, Abdellatif, Meckenstock, Roderich, Didier, Morgane, Haroche, Julien, Clement, Annick, Bernaudin, Jean-François, Nunes, Hilario, Valeyre, Dominique, Nathan, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408766/
https://www.ncbi.nlm.nih.gov/pubmed/32635292
http://dx.doi.org/10.3390/jcm9072097
Descripción
Sumario:(1) Background: Pediatric sarcoidosis is a rare and mostly severe disease. Very few pediatric series with a prolonged follow-up are reported. We aimed to evaluate the evolution of pediatric sarcoidosis in adulthood. (2) Material and methods: Patients over 18-years-old with a pediatric-onset sarcoidosis (≤15-year-old) who completed at least a three-year follow-up in French expert centers were included. Clinical information at presentation and outcome in adulthood were studied. (3) Results: A total of 52 patients were included (34 prospectively in childhood and 18 retrospectively in adulthood), with a mean age of 12 (±2.7) at diagnosis. The median duration time of follow-up was 11.5 years (range 3–44.5). Relapses mostly occurred during treatment decrease (84.5%), others within the three years after treatment interruption (9.1%), and rarely when the disease was stable for more than three years (6.4%). Sarcoidosis was severe in 11 (21.2%) in adulthood. Patients received a high corticosteroid cumulative dose (median 17,900 mg) for a median duration of five years (range 0–32), resulting in mostly mild (18; 35.3%) and rarely severe (2; 3.8%) adverse events. (4) Conclusions: Pediatric-onset sarcoidosis needed a long-term treatment in almost half of the patients. Around one fifth of pediatric-onset sarcoidosis patients had severe sarcoidosis consequences in adulthood.